These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 103551)

  • 1. Comparative disposition of sulindac and metabolites in five species.
    Duggan DE; Hooke KF; Noll RM; Hucker HB; Van Arman CG
    Biochem Pharmacol; 1978; 27(19):2311-20. PubMed ID: 103551
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of Sulindac.
    Kwan KC; Duggan DE
    Acta Rhumatol Belg; 1977; 1(3-4):168-78. PubMed ID: 756665
    [No Abstract]   [Full Text] [Related]  

  • 3. In vitro metabolism of sulindac and sulindac sulfide: enzymatic formation of sulfoxide and sulfone.
    Kitamura S; Tatsumi K
    Jpn J Pharmacol; 1982 Oct; 32(5):833-8. PubMed ID: 7176218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation.
    Duggan DE; Hooke KF; Hwang SS
    Drug Metab Dispos; 1980; 8(4):241-6. PubMed ID: 6105058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enterohepatic circulation of sulindac and metabolites.
    Dujovne CA; Pitterman A; Vincek WC; Dobrinska MR; Davies RO; Duggan DE
    Clin Pharmacol Ther; 1983 Feb; 33(2):172-7. PubMed ID: 6822030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary secretion of sulindac and metabolites in man.
    Dobrinska MR; Furst DE; Spiegel T; Vincek WC; Tompkins R; Duggan DE; Davies RO; Paulus HE
    Biopharm Drug Dispos; 1983; 4(4):347-58. PubMed ID: 6661513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. II. Differential effects on the biliary excretion.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):608-13. PubMed ID: 2865112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal metabolism of sulindac, a novel nonsteroidal antiinflammatory agent.
    Miller MJ; Bednar MM; McGiff JC
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():487-91. PubMed ID: 6221568
    [No Abstract]   [Full Text] [Related]  

  • 9. Sulindac: therapeutic implications of the prodrug/pharmacophore equilibrium.
    Duggan DE
    Drug Metab Rev; 1981; 12(2):325-37. PubMed ID: 7040018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic pathways of aprindine.
    Murphy PJ
    Acta Cardiol; 1974; Suppl 18():131-42. PubMed ID: 4213697
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dimethyl sulfoxide on sulindac disposition in rats.
    Swanson BN; Mojaverian P; Boppana VK; Dudash MR
    Drug Metab Dispos; 1981; 9(6):499-502. PubMed ID: 6120805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfoxide reduction. In vitro reduction of sulindac by rat hepatic cytosolic enzymes.
    Ratnayake JH; Hanna PE; Anders MW; Duggan DE
    Drug Metab Dispos; 1981; 9(2):85-7. PubMed ID: 6113122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulindac, reactive oxygen, and arthritis.
    Bodaness RS
    Med Hypotheses; 1979 Oct; 5(10):1129-30. PubMed ID: 522698
    [No Abstract]   [Full Text] [Related]  

  • 16. Dimethyl sulfoxide inhibits metabolic activation of sulindac.
    Swanson BN; Mojaverian P; Boppana VK; Vlasses PH; Ferguson RK
    Ann N Y Acad Sci; 1983; 411():381-2. PubMed ID: 6576719
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of sulindac and metabolites in plasma and urine by high-performance liquid chromatography.
    Stubbs RJ; Ng LL; Entwistle LA; Bayne WF
    J Chromatogr; 1987 Jan; 413():171-80. PubMed ID: 3558666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thioredoxin-dependent sulfoxide reduction by rat renal cytosol.
    Anders MW; Ratnayake JH; Hanna PE; Fuchs JA
    Drug Metab Dispos; 1981; 9(4):307-10. PubMed ID: 6114827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The reduction of sulphinpyrazone and sulindac by intestinal bacteria.
    Strong HA; Renwick AG; George CF; Liu YF; Hill MJ
    Xenobiotica; 1987 Jun; 17(6):685-96. PubMed ID: 3630204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition and metabolism of fenbufen in several laboratory animals.
    Chiccarelli FS; Eisner HJ; Van Lear GE
    Arzneimittelforschung; 1980; 30(4A):707-15. PubMed ID: 6776965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.